Business Wire

STEMCELL Technologies Celebrates 30 Years With Unprecedented Annual Growth


STEMCELL Technologies, Canada’s largest biotechnology company, is marking its 30th year of accelerating research into cancer and other diseases by celebrating its culture of collaboration, curiosity, and discovery.

This press release features multimedia. View the full release here:

To view this piece of content from, please give your consent at the top of this page.

In July 2023, STEMCELL Technologies is marking its 30th year of accelerating research into cancer and other diseases by celebrating its culture of collaboration, curiosity, and discovery. STEMCELL is Canada’s largest biotechnology company and is headquartered in Vancouver, British Columbia. (Photo: Business Wire)

“STEMCELL has come a long way in the last 30 years, and by growing our talented team we are well-positioned to achieve even more in the decades to come,” said Founder, President, and CEO Dr. Allen Eaves. “Through our ever-expanding portfolio of high-quality products and services, we are supporting cancer research by making culture media for growing the stem cells of tissues that are prone to cancer, including blood, brain, breast, intestine, kidney, liver, lung, pancreas, prostate, and skin cells. This has enabled us to build unparalleled trust and confidence within the global scientific community.”

In July of 1993, Dr. Eaves remortgaged his home and obtained a government business loan to start STEMCELL and commercialize a reliable source of cell culture media for growing the blood-forming stem cells that can result in leukemia when they go wrong. This media, which he called MethoCult™, is now the global standard for growing blood-forming stem cells. Today, STEMCELL sells more than 2,500 other products, including specialized media, growth factors, monoclonal antibodies, cell separation reagents, instruments, plasticware, and contract assay services.

STEMCELL’s story originates in the 1980s when Dr. Eaves was Director of the Vancouver-based Terry Fox Laboratory. His team was working to understand how growth factors cause blood stem cells to give rise to white and red cells, and what goes wrong in cases of leukemia. This work required cell culture media with raw materials that were carefully selected to produce reproducible growth from one experiment to the next. Soon colleagues in other institutions wanted to use this media so their results could be compared both internally and between labs in other institutions.

As a privately held company, STEMCELL has averaged 20 percent annual growth since its inception. This has been accomplished by putting all profits back into research, facilities, and sustainability initiatives. Ninety-seven percent of its sales are outside Canada to over 25,000 customers globally. Warehouses in Burnaby, Seattle, Grenoble, Melbourne, Singapore, and Beijing allow rapid delivery of products around the world.

With sales staff in 20 countries and distributors in 80 other countries, STEMCELL is a company of scientists helping scientists. Of its 2,300 global employees, 1,800 are based in Canada. Deeply rooted in education, the company provides on-site and virtual training programs, as well as 21 tissue-specific weekly newsletters as part of a Science News program with more than 200,000 readers. This helps ensure scientists are trained and prepared to conduct reproducible research effectively and efficiently. For its own staff, STEMCELL offers over 1,700 training courses, either in-person or virtually.

“As a major biotech anchor company, STEMCELL’s commitment to science and the advancement of research is as strong as ever, and I’m excited about the future,” Dr. Eaves said. “Our growing team will continue to play an important role in ensuring there is continued progress and innovation in life science research here in Canada and globally.”

"STEMCELL is a leading innovator and has played an integral role in building up Canada's life science and biotechnology ecosystem,” said Sue Paish, CEO, DIGITAL. “STEMCELL's commitment to scientists and to their growth in Canada and around the world is impressive. Congratulations on 30 years, and I look forward to watching what the team accomplishes in the next decade."

About STEMCELL Technologies

STEMCELL Technologies supports life sciences research with more than 2,500 specialized reagents, tools, and services. STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.

To view this piece of content from, please give your consent at the top of this page.

Contact information

For more information and to arrange an interview:
Ryan-Sang Lee
Senior Manager, Corporate Communications, STEMCELL Technologies

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress29.9.2023 20:43:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin. “We are pleased to add to the data supporting the use of ruxolitinib cream for patients living with vitiligo and atopic dermatitis (AD) through two late-breaking presentations – one on prolonged use of treatment in vitiligo patients with limited or no initial response, and the full results of our TRuE-AD3 trial in pediatric AD,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte. “Collectively, the data at this year's Congress, which also include new late-breaking data for povorcitinib in vitiligo, emphasize our ongoing efforts to advance treatment options for the Dermatology community." Key abstracts from Incyte-sponsored programs include: Late-breaking Oral Presentations Vitiligo Efficacy an

Q4 Inc. Recognized as one of Canada’s Top Growing Companies by The Globe and Mail29.9.2023 17:30:00 EEST | Press release

Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), the leading capital markets access platform, is pleased to announce their ranking on the 2023 Report on Business of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Q4 earned its spot with three-year growth of 150%. “We are honored to be recognized as one of Canada’s Top Growing Companies for the fourth consecutive year by The Globe and Mail,” remarked Darrell Heaps, Founder and CEO of Q4. “We are proud of the growth we have achieved as a company and this recognition is a true reflection of our dedication to helping our clients win in the capital markets through innovative technology on the Q4 Platform.” Canada’s Top Growing Companies is an editorial ranking that was launched in 2019. It aims to bring the accomplishments of innovative businesses in Canada to the forefront. In order to qualify for this voluntary program; companies had to complete an in-depth application proc

GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine29.9.2023 16:15:00 EEST | Press release

GEDi Cube Intl Ltd. (GEDi Cube), an AI medical technology company, and Renovaro Biosciences Inc. (NASDAQ:RENB) (Renovaro), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy, have signed a definitive agreement to combine, in which GEDi Cube will become a wholly-owned subsidiary of Renovaro in a stock-for-stock acquisition (the “Transaction”). If completed, the Transaction will result in a combined company that will offer advanced early diagnosis and early identification of recurring cancer as well as potential therapies for several critical diseases such as pancreatic cancer and other solid tumors with poor life expectancy. The combined company will have a unique advantage: Renovaro Biosciences’ pre-clinical and clinical trial data could be utilized to accelerate GEDi Cube’s AI capabilities that, in turn, could potentially help to accelerate Renovaro’s development of potential new therapies. AI will be used to advance the fields of diagnosis and treatment with

Offshore Windfarm Hollandse Kust Zuid Inaugurated29.9.2023 14:53:00 EEST | Press release

Today, Dutch King Willem-Alexander jointly with the board members of Vattenfall, BASF, and Allianz officially inaugurated the offshore wind farm Hollandse Kust Zuid 1-4. The wind farm is in the North Sea, 18-36 kilometers off the Dutch coast between the towns of Scheveningen and Zandvoort. The 139 turbines have a total capacity of 1.5 GW, making it one of the largest offshore wind farms in the world. The annual electricity production is expected to equal the consumption of 1.5 million households. Hollandse Kust Zuid is owned by Vattenfall, BASF, and Allianz. The wind farm is expected to be fully operational in 2024 and will be serviced out of the port of IJmuiden. This press release features multimedia. View the full release here: Inauguration Hollandse Kust Zuid wind farm. From left to right: Helene Biström (Senior Vice President, Head of Business Area Wind Vattenfall), Martijn Hagens (CEO Vattenfall Netherlands), His Majesty K

The Estée Lauder Companies Launches 2023 Breast Cancer Campaign: Beautifully United to Help End Breast Cancer29.9.2023 14:00:00 EEST | Press release

For more than 30 years, The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign) has been dedicated to advancing the possibility of a breast cancer-free world for all. This October, The Estée Lauder Companies (ELC) honors Breast Cancer Awareness Month by launching The Campaign in support of the global breast cancer community. As ELC’s largest corporate social impact program, The Campaign continues to inspire purpose-driven action and is a cornerstone of the company’s social investments in women’s advancement, health and education. Through The Campaign, ELC has also been a longstanding supporter of women in science, research and medicine – funding numerous grants and programs around the world and accelerating opportunities for women in STEM. The Campaign was founded by Evelyn H. Lauder in 1992 with the launch of the iconic Pink Ribbon. At a time when breast cancer wasn’t spoken about openly, Evelyn and ELC saw an opportunity to bring awareness to the disease and address stigmas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom